HRS-5817 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-5817 injection in healthy or obese subjects with single and multiple doses. (clinicaltrials.gov) - P1 | N=146 | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | N=92 ➔ 146

Enrollment change • Genetic Disorders • Obesity

A Trial of HRS-5817 in Obese Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Atridia Pty Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Trial of HRS-5817 in Obese Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Trial of HRS-5817 in Obese Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Atridia Pty Ltd.

New P1 trial • Genetic Disorders • Obesity

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | N=44 ➔ 92 | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P1 trial • Genetic Disorders • Obesity